{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Small+Cell+Lung&page=11", "query": { "condition": "Carcinoma, Small Cell Lung", "page": 11 }, "page_size": 10 }, "pagination": { "page": 11, "page_size": 10, "total_count": 4122, "total_pages": 413, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Small+Cell+Lung&page=12&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma%2C+Small+Cell+Lung&page=10&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T12:26:37.392Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "Tarlatamab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 184, "start_date": "2022-08-24", "completion_date": "2030-05-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 9, "location_summary": "Los Angeles, California • Newark, Delaware • Detroit, Michigan + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05361395" }, { "nct_id": "NCT04332367", "title": "Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2020-08-01", "completion_date": "2026-09-30", "has_results": false, "last_update_posted_date": "2026-06-10", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04332367" }, { "nct_id": "NCT05785767", "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "fianlimab", "type": "DRUG" }, { "name": "cemiplimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2023-06-30", "completion_date": "2027-09-28", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 23, "location_summary": "Tucson, Arizona • Yuma, Arizona • Redlands, California + 20 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Yuma", "state": "Arizona" }, { "city": "Redlands", "state": "California" }, { "city": "Norwich", "state": "Connecticut" }, { "city": "Clermont", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05785767" }, { "nct_id": "NCT00085839", "title": "Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Tarceva (Trademark) (erlotinib HCl, OSI-774)", "type": "DRUG" }, { "name": "Combination carboplatin and paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OSI Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 103, "start_date": "2004-02", "completion_date": "2007-03", "has_results": true, "last_update_posted_date": "2012-08-09", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 19, "location_summary": "Greenbrae, California • San Diego, California • Fort Lauderdale, Florida + 16 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085839" }, { "nct_id": "NCT03860272", "title": "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Angiosarcoma", "Colorectal Cancer Without Liver Metastases", "Endometrial Cancer", "Fibrolamellar Carcinoma", "Non-small-cell Lung Cancer", "Ovarian Cancer", "Prostate Cancer" ], "interventions": [ { "name": "Botensilimab", "type": "DRUG" }, { "name": "Balstilimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Agenus Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 499, "start_date": "2019-03-20", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 17, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03860272" }, { "nct_id": "NCT00082472", "title": "Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC" ], "interventions": [ { "name": "Doxorubicin HCl Inhalation Solution", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Zivena", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2006-04-18", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Las Vegas, Nevada • The Bronx, New York + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "The Bronx", "state": "New York" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00082472" }, { "nct_id": "NCT03412877", "title": "Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocrine Tumors", "Non-Small Cell Lung Cancer", "Ovarian Cancer", "Breast Cancer", "Gastrointestinal/Genitourinary Cancers", "Neuroendocrine Tumors", "Multiple Myeloma" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Individual Patient TCR-Transduced PBL", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab (KEYTRUDA(R))", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "72 Years", "sex": "ALL", "summary": "18 Years to 72 Years" }, "enrollment_count": 285, "start_date": "2018-09-06", "completion_date": "2029-03-23", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03412877" }, { "nct_id": "NCT01413451", "title": "Amatuximab for High Mesothelin Cancers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Carcinoma, Pancreatic Ductal", "Mesothelioma", "Ovarian Neoplasms", "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "Amatuximab (MORab-009)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 7, "start_date": "2011-07-12", "completion_date": "2013-11-15", "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413451" }, { "nct_id": "NCT01415739", "title": "Study of Proteins in Tumor Samples From Patients With Non-Small Cell Lung Cancer", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2011-10", "completion_date": "2015-08", "has_results": false, "last_update_posted_date": "2019-01-24", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01415739" }, { "nct_id": "NCT00590902", "title": "Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bronchioloalveolar Cell Variant of Non-small Cell Lung Cancer" ], "interventions": [ { "name": "OSI-774: erlotinib, TarcevaTM", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 81, "start_date": "2002-03", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2023-10-16", "last_synced_at": "2026-10-14T12:26:37.392Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590902" } ] }